Revenues (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):


	Three months ended June 30,
	2024						2023
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	770	$	395	$	1,165	$	691	$	337	$	1,028
ENBREL	902		7		909		1,055		13		1,068
XGEVA	399		163		562		387		143		530
Repatha	270		262		532		212		212		424
Otezla	432		112		544		495		105		600
TEPEZZA(1)	478		1		479		—		—		—
KYPROLIS	240		137		377		234		112		346
EVENITY	281		110		391		192		89		281
Aranesp	91		257		348		123		242		365
Nplate	214		132		346		176		134		310
KRYSTEXXA(1)	294		—		294		—		—		—
Vectibix	133		137		270		118		130		248
BLINCYTO	165		99		264		145		61		206
TEZSPIRE(2)	234		—		234		133		—		133
Other products(3)	937		389		1,326		775		369		1,144
Total product sales(4)	$	5,840	$	2,201	8,041		$	4,736	$	1,947	6,683
Other revenues					347						303
Total revenues					$	8,388					$	6,986
























	Six months ended June 30,
	2024						2023
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	1,427	$	737	$	2,164	$	1,314	$	641	$	1,955
ENBREL	1,463		13		1,476		1,619		28		1,647
XGEVA	765		358		1,123		771		295		1,066
Repatha	543		506		1,049		409		403		812
Otezla	725		213		938		789		203		992
TEPEZZA(1)	897		6		903		—		—		—
KYPROLIS	474		279		753		468		236		704
EVENITY	517		216		733		356		179		535
Aranesp	191		506		697		238		482		720
Nplate	404		259		663		422		250		672
KRYSTEXXA(1)	529		—		529		—		—		—
Vectibix	253		264		517		229		252		481
BLINCYTO	318		190		508		271		129		400
TEZSPIRE(2)	407		—		407		229		—		229
Other products(3)	1,900		799		2,699		1,596		720		2,316
Total product sales(4)	$	10,813	$	4,346	15,159		$	8,711	$	3,818	12,529
Other revenues					676						562
Total revenues					$	15,835					$	13,091

_______

(1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.

(2) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(3) Consists of product sales of our non-principal products.

(4) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2024 and 2023.